Treatment of Cerebral Atrophy with Microvascular Changes

Risk Factor Management

The American College of Cardiology recommends intensive blood pressure control with a target systolic BP <120 mmHg for individuals over 50 with BP >130 mmHg, as it is the cornerstone of treatment, with evidence showing a linear relationship between lower blood pressure and reduced risk of vascular cognitive impairment 1
Antihypertensive therapy should be strongly considered for individuals with average diastolic BP ≥90 mmHg or systolic BP ≥140 mmHg to prevent further progression of microvascular damage, with a strength of evidence supporting its effectiveness 1
Management of diabetes mellitus is essential, as it increases the risk of cerebrovascular disease approximately 2 times, according to the American Diabetes Association 2
Dyslipidemia control should follow established guidelines, with target LDL-C <100 mg/dL and <70 mg/dL for very high-risk individuals, as recommended by the American Heart Association 2
Smoking cessation is critical as it represents a significant modifiable risk factor for cerebrovascular disease, with a strong evidence base supporting its importance 1
These vascular risk factors directly contribute to different types of cerebrovascular diseases including atherosclerosis, arteriolosclerosis, and microvascular disease, as stated by the Journal of the American College of Radiology 3

Cholinesterase inhibitors may be considered for individuals with vascular or mixed dementia, with evidence showing small but meaningful benefits in cognitive outcomes, according to the American Academy of Neurology 1
Donepezil 10mg has demonstrated the best cognitive benefit among cholinesterase inhibitors, though it also has the highest rate of side effects, with a moderate strength of evidence supporting its use 1
Memantine has shown small improvements in cognitive function in individuals with vascular dementia and may be considered as an alternative or adjunct therapy, with a low to moderate strength of evidence supporting its effectiveness 1

MRI is recommended over CT for investigating vascular cognitive impairment and monitoring disease progression, as stated by the Journal of the American College of Radiology 3
White matter hyperintensities should be assessed using a validated visual rating scale such as the Fazekas scale to quantify disease severity, with a high strength of evidence supporting its use 1
Beginning confluent or confluent subcortical white matter hyperintensities are often sufficient to cause clinical cognitive impairment and warrant aggressive treatment, according to the American Academy of Neurology 1
Amyloid PET/CT may be useful in identifying mixed pathology, as it is positive in up to 25% of patients with clinical vascular dementia, with a moderate strength of evidence supporting its use 3

Blood-brain barrier dysfunction plays a pivotal role in the early development of cSVD and represents an important pathophysiological mechanism, as stated by the Alzheimer's Association 4
The neurovascular unit (neurons, glia, and vascular cells) functions as an integrated system, and disruption of this unit contributes to disease progression, with a high strength of evidence supporting its importance 5

Regular monitoring of blood pressure control is essential, as even small reductions can significantly impact disease progression, with a strong evidence base supporting its importance 1
Mixed pathology (vascular and Alzheimer's) is common, with a prevalence of up to 38% in neuropathologic studies, and the probability increases with age, as stated by the Journal of the American College of Radiology 3